Target intelligence / Profile preview

Mast cell immunoglobulin-like receptor 1 (MILR1)

Target
MILR1
Molecular classification
Receptor, Immunoglobulin-like receptor, Transmembrane signaling receptor
01

Overview

Mast cell immunoglobulin-like receptor 1 (MILR1), also known as Allergin-1, is a transmembrane inhibitory receptor primarily expressed on mast cells[1][2][6]. This receptor belongs to the immunoglobulin superfamily and operates by negatively regulating IgE-mediated mast cell activation, thereby suppressing degranulation and limiting type I immediate hypersensitivity responses (allergic reactions)[1][2]. MILR1 is localized at the plasma membrane where it functions as a cell surface signaling receptor[1][2]. It has potential relevance in allergic diseases, mitochondrial disorders, and variable expression across cancer tissues, although its role as a direct therapeutic drug target remains under investigation[1][4][6].

Other names
Allergin-1C17orf60MCA-32MCA32allergy inhibitory receptor 1mast cell antigen 32probable mast cell antigen 32 homolog
02

Mechanism of action

Drugs would act by modulating receptor function to regulate mast cell activation (hypothetical, specific clinical drugs not listed in current sources)

03

Biological functions

Negative regulation of mast cell activationInhibition of mast cell degranulationRegulation of IgE-mediated immediate hypersensitivity reactionCell surface receptor signaling pathway
04

Disease associations

Allergic disease (modulates IgE-mediated hypersensitivity)Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4Mitochondrial DNA depletion syndrome 16BCancer (variable expression in multiple cancer types, may have prognostic relevance)
05

Safety considerations

Potential risk of immunomodulation—modifying MILR1 activity could inadvertently alter mast cell responses, impacting allergic or immune reactions (speculative, not described in the primary literature)
06

Biomarkers

Expression level of MILR1 could be a biomarker for hypersensitivity disease and possibly cancer prognosis (supported by tissue/cancer expression studies)

Beyond the preview

Go deeper on Mast cell immunoglobulin-like receptor 1 (MILR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mast cell immunoglobulin-like receptor 1 (MILR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call